CDTTW (NASDAQ) is a cross-listing of CDT (NASDAQ). Showing primary listing data.
CDT
CDT Equity Inc.
1W: -14.0%
1M: -36.4%
3M: -73.8%
YTD: -69.7%
1Y: -99.6%
3Y: -100.0%
$0.43
-0.06 (-12.01%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.6M
52W Range0.371-168
Volume284,851
Avg Volume686,362
Beta1.81
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAndrew Regan
Employees6
SectorHealthcare
IndustryBiotechnology
IPO Date2022-03-28
Websiteconduitpharma.com
4581 Tamiami Trail North
Naples, FL 34103
US
Naples, FL 34103
US
646 491 9132
About CDT Equity Inc.
CDT Equity, Inc. engages in facilitating the development and commercialization of clinical assets. The company was founded by David Joszef Tapolczay and Freda C. Lewis-Hall in October 2021 is headquartered in Naples, FL.
Latest News
CDT Equity announces reverse stock split
CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy
12 Health Care Stocks Moving In Monday's Pre-Market Session
CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence
CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Farley Chele Chiavac | A-Award | 10,553 | $1.04 | 2026-02-19 |
| Farley Chele Chiavac | A-Award | 1,940,804 | $0.00 | 2026-02-19 |
| Regan Andrew | A-Award | 224,800 | $1.79 | 2025-12-08 |
| Regan Andrew | A-Award | 3,685,815 | $0.00 | 2025-12-08 |
| Regan Andrew | A-Award | 1,120,000 | $0.69 | 2025-09-19 |